1 / 7

Combination Topical Products for the Treatment of Acne Vulgaris

Combination Topical Products for the Treatment of Acne Vulgaris. Markham C. Luke, M.D., Ph.D. Dermatology Clinical Team Leader DDDDP, ODE V, CDER, FDA. Fixed-combination Drugs.

cooper
Download Presentation

Combination Topical Products for the Treatment of Acne Vulgaris

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Combination Topical Products for the Treatment of Acne Vulgaris Markham C. Luke, M.D., Ph.D. Dermatology Clinical Team Leader DDDDP, ODE V, CDER, FDA

  2. Fixed-combination Drugs “Two or more drugs may be combined in a single dosage form when each component makes a contribution to the claimed effects and the dosage of each component (amount, frequency, duration) is such that the combination is safe and effective for a significant patient population requiring such concurrent therapy as defined in the labeling for the drug.” - 21 CFR 300.50 (a)

  3. Acne Combination Drugs Combination topical products for the treatment of acne vulgaris require evidence for the contribution of each active component or components that are purported to provide for added efficacy.

  4. Fixed-combination Policy Applying the combination drug policy for 2 drugs, component substances A and B having the same endpoint, in a three or four arm clinical trial, success is demonstrated by: (A + B) > A, B > placebo

  5. Acne Combination Drugs • Currently marketed combination topical drug products for acne have combined a topical antibiotic (erythromycin or clindamycin) [= A] with benzoyl peroxide [= B]. • The safety and efficacy of other combinations for the treatment of acne are also being investigated.

  6. Acne Combination Drugs Studies to address the combination policy for acne drugs have shown that the most difficult superiority to demonstrate is the contribution of the antibiotic to the efficacy already achievable with benzoyl peroxide alone: (A + B) > B

  7. Conclusion • Each component of a fixed combination drug for the treatment of acne must demonstrate a contribution to the claimed effects of the drug product. • This may be difficult if the contribution of one of the actives (e.g., topical antibiotic) is minimal and hard to discern when combined with another active (e.g., benzoyl peroxide).

More Related